Microflox Tablets (Ciprofloxacin)

• Composition :
  Each tablet contains Ciprofloxacin250mg/500mg Tablets.
• Indications :
  Indicated in the treatment of respiratory tract infection, UTI, skin & soft tissue, severe systemic infections, surgical, gynecological, G.I, bone & joint infections and STD.
• Pharmacodynamics :
  The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial DNA replication, transcription, repair, and recombination.
• Dosage and administration :
  RTI, skin and soft tissue infections, severe systemic infections, surgical, gynecological, G.I, bone & joint infection: 500 mg- 750mg every 12 hours. UTI: 250mg -500 mg every 12 hours. Uncomplicated Gonorrhea: 250mg as a single dose.
• Contraindications :
  Known hypersensitivity to ciprofloxacin (including other quinolones) and other ingredients of the product.
• Precautions and warnings :
  Hypersensitivity and other serious reactions: Serious and sometimes fatal reactions (for example, anaphylactic reactions) may occur after the first or subsequent doses of ciprofloxacin. Discontinue ciprofloxacin at the first sign of skin rash, jaundice or any sign of hypersensitivity. Hepatotoxicity: Discontinue immediately if signs and symptoms of hepatitis occur. Clostridium difficile-associated diarrhea: Evaluate if colitis occurs. QT Prolongation: Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval.Tendinitis and tendon rupture can occur,Peripheral neuropathy can occur.
• Use in pregnancy, lactation & pediatrics :
  Pregnancy Category C. Should not be used during pregnancy unless the potential benefit justifies the potential risk to both fetus and mother.Ciprofloxacin is excreted in human milk. Because of the potential risk of serious adverse reactions (including articular damage) in infants nursing from mothers taking drug, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Safety and efficacy of ciprofloxacin tablets in pediatric population is not established.
• Drug interactions :
  Theophylline: Serious and fatal reactions. Avoid concomitant use and monitor serum level. Warfarin: Anticoagulant effect enhanced. Monitor prothrombin time, INR, and bleeding. Antidiabetic agents: Hypoglycemia including fatal outcomes have been reported. Monitor blood glucose. Phenytoin: Use with caution Altered serum levels of phenytoin (increased and decreased). Methotrexate Monitor for methotrexate toxicity. Cyclosporine: May increase serum creatinine. Multivalent cationcontaining products including antacids, metal cations or didanosine: decreasesciprofloxacin absorption. Take 2 hours before or 6 hours after ciprofloxacin.
• Adverse reactions :
  The most common adverse reactions are nausea, diarrhea, abnormal function tests, vomiting, and rash.
• Therapy Area :
  Anti-Bacterials